Generated by AI
Savara Inc. is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The company’s work centers on developing inhaled therapies designed to address serious lung disorders with limited treatment options, with a particular emphasis on autoimmune pulmonary alveolar proteinosis. Its lead product candidate, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor being advanced through late-stage clinical development. Savara’s current business is concentrated on research, clinical development, and regulatory progress in orphan and specialty respiratory medicine, rather than on a broad commercial product portfolio. The company serves a niche market within biotechnology and pharmaceuticals, where expertise in pulmonary medicine and rare disease development is central to its role.
Website1717 Langhorne Newtown Road
Langhorne, PA, 19047
United States
The latest articles about SVRA.
Summary of Nov 18's posts. Generated by AI.
Summary of Jun 26's posts. Generated by AI.
Summary of May 27's posts. Generated by AI.
Summary of Nov 18's posts. Generated by AI.
Investors talking about SVRA also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.